Table 1.

Characteristics of enrolled children, RMP dose per kg of body weight, and administration by nasogastric tube on the day of pharmacokinetic evaluation by RMP formulation

Formulation	Eremfat® RMP (n = 92) median [IQR]	R-Cin® RMP (n = 54) median [IQR]	P value
Age, years	1.97 [0.94–4.37]	0.88 [0.5–2.47]	< 0.001
Weight, kg	11.48 [8.27–15.45]	8.37 [5.7–13.3]	< 0.001
HIV-infected, n (%)*	5 (5)	6 (11)	0.217
Female, n (%)	43 (47)	17 (31)	0.070
Dose, mg/kg	14.95 [12.20–16.68]	16.51 [14.85–18.67]	0.002
Nasogastric tube, n (%)	14 (15)	26 (48)	< 0.001

^*At the time of pharmacokinetic sampling, four children had not started antiretroviral treatment, one child was receiving an efavirenz-based regimen and the remaining children were on lopinavir/ritonavir with two nucleoside reverse transcriptase inhibitors.

RMP = rifampicin; IQR = interquartile range; HIV = human immunodeficiency virus.